
    
      This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with
      metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with 1
      of 3 different concentrations of PA2024 antigen The primary purpose of this study is to
      compare the changes in CD54 upregulation between each of these 3 groups of subjects.
    
  